| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.12 | KE:288 | Activation of specific nuclear receptors, Transcriptional change |
| AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus | 0.2 | KE:754 | Increased, Luteinizing hormone (LH) |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.33 | KE:747 | Decreased, Prolactin |
| KE:749 | Decreased, Progesterone from corpus luteum | ||||||
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.2 | KE:791 | Increased, Leutinizing hormone (LH) |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.14 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | Fish | 0.29 | KE:1693 | Reduction, Plasma progesterone concentration |
| KE:1692 | Reduction, Progesterone synthesis | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.67 | KE:1065 | Activation, estrogen receptor alpha |
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.6 | KE:2294 | Plasma estradiol, increased |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:2251 | Estradiol availability, increased | ||||||
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:2305 | Premature ovarian Insufficiency |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha | |
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.